ProNAi Therapeutics is applying proprietary, nucleic acid-based DNA interference technology (DNAi®) to discover and develop novel therapeutic approaches for cancer and other diseases. The company was founded in 2004 by pharmaceutical researchers and scientists who have substantial experience in the area of nucleic acid research in cancer. The company's most advanced drug candidate, PNT2258, has striking clinical and preclinical activity in hematological and solid tumor models. ProNAi received approval to proceed into Phase 1 clinical testing from the FDA for PNT2258 and in September 2010 began those trials. The safety and efficacy results from the Phase I study conducted at START in Texas in refractory solid tumor patients were presented at EORTC in November 2012. Phase II trials have started in refractory NHL patients at clinical sites in the Midwest.
The company has successfully recruited a seasoned senior management team and a Board of Directors with a proven track record in research, clinical operations, product development, and business development. ProNAi's Scientific and Medical Advisory Board has significant experience in cancer, nucleic acid research, and clinical trial design and development.